Covid-19 roundup: Lil­ly/In­cyte's Olu­mi­ant plus remde­sivir com­bo whiffs PhI­II; France rec­om­mends mix­ing vac­cines among younger As­traZeneca re­cip­i­ents

Eli Lil­ly has won three emer­gency use au­tho­riza­tions for Covid-19 treat­ments, two for its an­ti­body cock­tail con­tain­ing bam­lanivimab and one fea­tur­ing its In­cyte-parn­tered drug Olu­mi­ant, in com­bi­na­tion with Gilead’s remde­sivir. But the US stopped dis­trib­ut­ing bam­lanivimab a few weeks ago, and now Lil­ly is fac­ing more ques­tions over Olu­mi­ant’s ef­fec­tive­ness in Covid-19.

In a Phase III study re­port­ed Thurs­day, Olu­mi­ant did not meet its pri­ma­ry end­point. The drug failed to reach sta­tis­ti­cal sig­nif­i­cance for the dif­fer­ence in rate of pa­tients need­ing non-in­va­sive or in­va­sive ven­ti­la­tion for the first time, or those who died af­ter four weeks.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER